Unity Biotechnology
TypePublic
IndustryBiotechnology, Pharmaceutical
PredecessorForge, Inc.
Founded2011 (2011) in California, United States of America
Founders
Headquarters
South San Francisco, California
,
United States of America
Number of employees
70 (2018)
Websiteunitybiotechnology.com

Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells.[1][2][3][4][5][6][7]

The company's products in development include UBX1325, which targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 2 clinical trials for diabetic macular edema as of October 2023).[8] In July 2022, the company reported positive results from its Phase 1 study.[9] The company then reported in April 2023 results from its Phase 2 study demonstrating that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in vision through 48 weeks.[10] They also include UBX 1967, a preclinical product targeting ophthalmologic diseases.[11][12][13] Both products are senolytic medicines.

On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.[14][12] Unity Biotechnology shares dropped 60% on August 17, 2020, after the company reported disappointing results from a clinical trial involving its then lead drug candidate, UBX0101, in patients with moderate-to-severe painful osteoarthritis.[15]

See also

References

  1. ↑ Brueck, Hilary (3 February 2016). "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 19 February 2018.
  2. ↑ Detrixhe, John (21 February 2018). "Crypto millionaires are funding research to reverse the aging process". Quartz (publication). Retrieved 19 February 2018.
  3. ↑ Herkewitz, William (19 February 2018). "Scientists Can Now Radically Expand the Lifespan of Mice—and Humans May Be Next". Popular Mechanics. Retrieved 19 February 2018.
  4. ↑ Ramsey, Lydia (10 November 2016). "A biotech startup that aims to rid our bodies of cells related to aging just got a big investment". Business Insider. Retrieved 19 February 2018.
  5. ↑ Scudellari, Megan (25 February 2017). "To Stay Young, Kill Zombie Cells". Scientific American. Retrieved 19 February 2018.
  6. ↑ Greenfieldboyce, Nell (3 February 2016). "Boosting Life Span By Clearing Out Cellular Clutter". Retrieved 19 February 2018.
  7. ↑ Baker, Darren (11 February 2016). "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan". Nature. 530 (7589): 184–189. doi:10.1038/nature16932. PMC 4845101. PMID 26840489.
  8. ↑ "Design for Phase 2B ASPIRE Study of UBX1325 for DME announced by UNITY". Modern Retina. 2023-06-22. Retrieved 2023-10-17.
  9. ↑ Bankhead, Charles (2022-07-14). "'Senolytic' Therapy Shows Promise in Neovascular Eye Disease". www.medpagetoday.com. Retrieved 2022-07-15.
  10. ↑ Garth, Eleanor (2023-05-10). "Getting comfortable with senotherapeutics". Longevity.Technology - Latest News, Opinions, Analysis and Research. Retrieved 2023-10-17.
  11. ↑ "S-1". www.sec.gov. Retrieved 2018-10-12.
  12. 1 2 "Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC | BioSpace". BioSpace. Retrieved 2018-10-12.
  13. ↑ "Unity Biotechnology to focus on senolytic programs in ophthalmology, neurology". www.healio.com. Retrieved 2020-12-08.
  14. ↑ CNBC (2018-05-02). "UNITY Biotechnology, Inc. Announces Pricing of Initial Public Offering of Common Stock". CNBC. Retrieved 2018-10-12.
  15. ↑ "Buzzy anti-aging biotech Unity drops leading program after flop, shares in freefall". 2020-08-17.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.